Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Head and Neck Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 96 articles:
HTML format



Single Articles


    June 2022
  1. ZHANG Z, Wu B, Peng G, Xiao G, et al
    Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial.
    Clin Cancer Res. 2022 Jun 29:OF1-OF9. doi: 10.1158/1078-0432.CCR-22-0666.
    PubMed     Abstract available


  2. SIHAG S, Nussenzweig SC, Walch HS, Hsu M, et al
    The Role of the TP53 Pathway in Predicting Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma.
    Clin Cancer Res. 2022;28:2669-2678.
    PubMed     Abstract available


  3. LEDDON JL, Gulati S, Haque S, Allen C, et al
    Phase 2 trial of adjuvant nivolumab following salvage resection in patients with recurrent squamous cell carcinoma of the head and neck.
    Clin Cancer Res. 2022 Jun 2. pii: 699312. doi: 10.1158/1078-0432.CCR-21-4554.
    PubMed     Abstract available


    May 2022
  4. WANG W, Lozar T, Golfinos AE, Lee D, et al
    Stress Keratin 17 Expression in Head and Neck Cancer Contributes to Immune Evasion and Resistance to Immune-Checkpoint Blockade.
    Clin Cancer Res. 2022 May 27:OF1-OF16. doi: 10.1158/1078-0432.CCR-21-3039.
    PubMed     Abstract available


  5. SCHMITD LB, Perez-Pacheco C, Bellile EL, Wu W, et al
    Spatial and Transcriptomic Analysis of Perineural Invasion in Oral Cancer.
    Clin Cancer Res. 2022 May 26. pii: 699248. doi: 10.1158/1078-0432.CCR-21-4543.
    PubMed     Abstract available


  6. DENEKA AY, Baca Y, Serebriiskii IG, Nicolas E, et al
    Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck Cancer.
    Clin Cancer Res. 2022;28:1925-1937.
    PubMed     Abstract available


    April 2022
  7. LE X, Gleber-Netto FO, Rubin ML, Qing Y, et al
    Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection.
    Clin Cancer Res. 2022 Apr 20. pii: 694632. doi: 10.1158/1078-0432.CCR-21-3239.
    PubMed     Abstract available


  8. FERRAROTTO R, Amit M, Nagarajan P, Rubin ML, et al
    Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.
    Clin Cancer Res. 2022;28:1735.
    PubMed    


  9. LEE AW, Ng WT, Choi CW, But B, et al
    Exploratory Study of NPC-0501 Trial - Optimal Cisplatin Dose of Concurrent and Induction/Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma.
    Clin Cancer Res. 2022 Apr 5. pii: 694221. doi: 10.1158/1078-0432.CCR-21-3375.
    PubMed     Abstract available


  10. GUIX I, Liu Q, Pujana MA, Ha P, et al
    Validation of Anticorrelated TGFbeta Signaling and Alternative End-Joining DNA Repair Signatures that Predict Response to Genotoxic Cancer Therapy.
    Clin Cancer Res. 2022;28:1372-1382.
    PubMed     Abstract available


    March 2022
  11. CHUNG CH, Li J, Steuer CE, Bhateja P, et al
    Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma.
    Clin Cancer Res. 2022 Mar 28. pii: 694028. doi: 10.1158/1078-0432.CCR-21-3849.
    PubMed     Abstract available


  12. OKADA M, Kato K, Cho BC, Takahashi M, et al
    Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3).
    Clin Cancer Res. 2022 Mar 16. pii: 682194. doi: 10.1158/1078-0432.CCR-21-0985.
    PubMed     Abstract available


  13. RICKELT S, Neyaz A, Condon C, Whittaker CA, et al
    Agrin Loss in Barrett's Esophagus-Related Neoplasia and Its Utility as a Diagnostic and Predictive Biomarker.
    Clin Cancer Res. 2022;28:1167-1179.
    PubMed     Abstract available


  14. OBRADOVIC A, Graves D, Korrer M, Wang Y, et al
    Immunostimulatory cancer-associated fibroblast subpopulations can predict immunotherapy response in head and neck cancer.
    Clin Cancer Res. 2022 Mar 9. pii: 682113. doi: 10.1158/1078-0432.CCR-21-3570.
    PubMed     Abstract available


    February 2022
  15. WISE-DRAPER TM, Gulati S, Palackdharry S, Hinrichs BH, et al
    Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2022 Feb 28:OF1-OF8. doi: 10.1158/1078-0432.CCR-21-3351.
    PubMed     Abstract available


  16. XU Y, Dong B, Zhu W, Li J, et al
    A phase III multicenter randomized clinical trial of 60 Gy vs 50 Gy radiation dose in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma.
    Clin Cancer Res. 2022 Feb 18. pii: 681705. doi: 10.1158/1078-0432.CCR-21-3843.
    PubMed     Abstract available


  17. SACCO AG, Cohen EEW
    Inevitable Progress-Relying on the Immune System, Not Chance.
    Clin Cancer Res. 2022;28:435-437.
    PubMed     Abstract available


    January 2022
  18. FERRIS RL, Moskovitz J, Kunning S, Ruffin AT, et al
    Phase I trial of cetuximab, radiation therapy, and ipilimumab in locally advanced head and neck cancer.
    Clin Cancer Res. 2022 Jan 28. pii: 1078-0432.CCR-21-0426.
    PubMed     Abstract available


  19. KAO HF, Liao BC, Huang YL, Huang HC, et al
    Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis.
    Clin Cancer Res. 2022 Jan 19. pii: 1078-0432.CCR-21-3025.
    PubMed     Abstract available


  20. LI Y, Yang X, Du X, Lei Y, et al
    Correction: RAB37 Hypermethylation Regulates Metastasis and Resistance to Docetaxel-Based Induction Chemotherapy in Nasopharyngeal Carcinoma.
    Clin Cancer Res. 2022;28:430.
    PubMed    


  21. CAO Y, Haring CT, Brummel C, Bhambhani C, et al
    Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma.
    Clin Cancer Res. 2022;28:350-359.
    PubMed     Abstract available


    December 2021
  22. WEBER P, Kunstner A, Hess J, Unger K, et al
    Therapy-related transcriptional subtypes in matched primary and recurrent head and neck cancer.
    Clin Cancer Res. 2021 Dec 29. pii: 1078-0432.CCR-21-2244.
    PubMed     Abstract available


  23. COHEN EEW, Nabell L, Wong DJ, Day T, et al
    Intralesional SD-101 in combination with pembrolizumab in anti-PD-1 treatment naive head and neck squamous cell carcinoma: results from a multicenter, phase 2 trial.
    Clin Cancer Res. 2021 Dec 29. pii: 1078-0432.CCR-21-1411.
    PubMed     Abstract available


  24. LUGINBUHL AJ, Johnson JM, Harshyne LA, Linnenbach AJ, et al
    Tadalafil enhances immune signatures in response to neoadjuvant nivolumab in resectable head and neck squamous cell carcinoma.
    Clin Cancer Res. 2021 Dec 15. pii: 1078-0432.CCR-21-1816.
    PubMed     Abstract available


  25. YAP TA, Vieito M, Baldini C, Sepulveda-Sanchez JM, et al
    First-In-Human Phase I Study of a Next-Generation, Oral, TGFbeta Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer.
    Clin Cancer Res. 2021;27:6666-6676.
    PubMed     Abstract available


  26. PANG J, Nguyen N, Luebeck J, Ball L, et al
    Extrachromosomal DNA in HPV-Mediated Oropharyngeal Cancer Drives Diverse Oncogene Transcription.
    Clin Cancer Res. 2021;27:6772-6786.
    PubMed     Abstract available


  27. TAYLOR MH, Betts CB, Maloney L, Nadler E, et al
    Safety and Efficacy of Pembrolizumab in Combination With Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study.
    Clin Cancer Res. 2021 Dec 3. pii: 1078-0432.CCR-21-2547.
    PubMed     Abstract available


  28. SIRAVEGNA G, O'Boyle CJ, Varmeh S, Queenan N, et al
    Cell free HPV DNA provides an accurate and rapid diagnosis of HPV-associated head and neck cancer.
    Clin Cancer Res. 2021 Dec 2. pii: 1078-0432.CCR-21-3151.
    PubMed     Abstract available


  29. EVEN C, Wang HM, Li SH, Ngan RK, et al
    Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer.
    Clin Cancer Res. 2021;27:6413-6423.
    PubMed     Abstract available


    November 2021
  30. KATABATHULA R, Joseph P, Singh S, Zhao S, et al
    Multi-scale Pan-cancer Integrative Analyses Identify the STAT3-VSIR Axis as a key Immunosuppressive Mechanism in Head and Neck Cancer.
    Clin Cancer Res. 2021 Nov 16. pii: 1078-0432.CCR-21-1978.
    PubMed     Abstract available


  31. BICKETT TE, Knitz M, Darragh LB, Bhatia S, et al
    FLT3L Release by Natural Killer Cells Enhances Response to Radioimmunotherapy in Preclinical Models of HNSCC.
    Clin Cancer Res. 2021;27:6235-6249.
    PubMed     Abstract available


  32. LEUNG E, Han K, Zou J, Zhao Z, et al
    HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA.
    Clin Cancer Res. 2021;27:5857-5868.
    PubMed     Abstract available


    October 2021
  33. HANNA GJ, ONeill A, Shin KY, Wong K, et al
    Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck.
    Clin Cancer Res. 2021 Oct 19. pii: 1078-0432.CCR-21-2635.
    PubMed     Abstract available


    September 2021
  34. ZHANG JX, Chen ZH, Xu Y, Chen JW, et al
    Correction: Downregulation of MicroRNA-644a Promotes Esophageal Squamous Cell Carcinoma Aggressiveness and Stem Cell-like Phenotype via Dysregulation of PITX2.
    Clin Cancer Res. 2021;27:4942.
    PubMed    


  35. DE LA IGLESIA JV, Slebos RJC, Martin-Gomez L, Wang X, et al
    Correction: Effects of Tobacco Smoking On the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2021;27:4941.
    PubMed    


    August 2021
  36. VYAS A, Harbison RA, Faden DL, Kubik M, et al
    Recurrent human papillomavirus-related head and neck cancer undergoes metabolic re-programming and is driven by oxidative phosphorylation.
    Clin Cancer Res. 2021 Aug 18. pii: 1078-0432.CCR-20-4789.
    PubMed     Abstract available


  37. XIA WX, Lv X, Liang H, Liu GY, et al
    A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer.
    Clin Cancer Res. 2021;27:4186-4194.
    PubMed     Abstract available


    July 2021
  38. ZHENG X, Xu Z, Ji Q, Ge M, et al
    A randomized, phase 3 study of lenvatinib in Chinese patients with radioiodine-refractory differentiated thyroid cancer.
    Clin Cancer Res. 2021 Jul 29. pii: 1078-0432.CCR-21-0761.
    PubMed     Abstract available


  39. BRAND TM, Hartmann S, Bhola NE, Peyser ND, et al
    Correction: Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV(+) Patients.
    Clin Cancer Res. 2021;27:4129.
    PubMed    


  40. KARPINETS TV, Mitani Y, Liu B, Zhang J, et al
    Whole-Genome Sequencing of Common Salivary Gland Carcinomas: Subtype-Restricted and Shared Genetic Alterations.
    Clin Cancer Res. 2021;27:3960-3969.
    PubMed     Abstract available


  41. CHENG NM, Yao J, Cai J, Ye X, et al
    Deep Learning for Fully Automated Prediction of Overall Survival in Patients with Oropharyngeal Cancer Using FDG-PET Imaging.
    Clin Cancer Res. 2021;27:3948-3959.
    PubMed     Abstract available


  42. LABIANO S, Roh V, Godfroid C, Hiou-Feige A, et al
    CD40 Agonist Targeted to Fibroblast Activation Protein alpha Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors.
    Clin Cancer Res. 2021;27:4054-4065.
    PubMed     Abstract available


  43. DE CLERCQ NC, van den Ende T, Prodan A, Hemke R, et al
    Fecal Microbiota Transplantation from Overweight or Obese Donors in Cachectic Patients with Advanced Gastroesophageal Cancer: A Randomized, Double-blind, Placebo-Controlled, Phase II Study.
    Clin Cancer Res. 2021;27:3784-3792.
    PubMed     Abstract available


    June 2021
  44. FERRAROTTO R, Amit M, Nagarajan P, Rubin ML, et al
    Pilot phase II trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.
    Clin Cancer Res. 2021 Jun 29. pii: 1078-0432.CCR-21-0585.
    PubMed     Abstract available


  45. BURGENER JM, Zou J, Zhao Z, Zheng Y, et al
    Tumor-Naive Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2021 Jun 22. pii: 1078-0432.CCR-21-0110.
    PubMed     Abstract available


  46. VAN DEN ENDE T, de Clercq NC, van Berge Henegouwen MI, Gisbertz SS, et al
    Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT).
    Clin Cancer Res. 2021;27:3351-3359.
    PubMed     Abstract available


  47. PAPPA T, Ahmadi S, Marqusee E, Johnson HL, et al
    Oncogenic mutations in PI3K/AKT/mTOR pathway effectors associate with worse prognosis in BRAF(V600E)-driven papillary thyroid cancer patients.
    Clin Cancer Res. 2021 Jun 4. pii: 1078-0432.CCR-21-0874.
    PubMed     Abstract available


  48. OPENSHAW MR, Pinato DJ, Valeri N
    Back from the Brink: EGFR Inhibition in Gastroesophageal Cancer.
    Clin Cancer Res. 2021;27:2964-2966.
    PubMed     Abstract available


  49. HEGDE A, Jayaprakash P, Couillault CA, Piha-Paul S, et al
    A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies.
    Clin Cancer Res. 2021;27:3050-3060.
    PubMed     Abstract available


  50. PENG Z, Wei J, Wang F, Ying J, et al
    Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
    Clin Cancer Res. 2021;27:3069-3078.
    PubMed     Abstract available


  51. CORSO S, Pietrantonio F, Apicella M, Migliore C, et al
    Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas.
    Clin Cancer Res. 2021;27:3126-3140.
    PubMed     Abstract available


    May 2021
  52. LEE RH, Kang H, Yom SS, Smogorzewska A, et al
    Treatment of Fanconi Anemia-Associated Head and Neck Cancer: Opportunities to Improve Outcomes.
    Clin Cancer Res. 2021 May 27. pii: 1078-0432.CCR-21-1259.
    PubMed     Abstract available


  53. KIM J, Bradford D, Larkins E, Pai-Scherf LH, et al
    FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid cancers with RET gene mutations or fusions.
    Clin Cancer Res. 2021 May 27. pii: 1078-0432.CCR-21-0967.
    PubMed     Abstract available


    April 2021
  54. LI D, Chi Y, Chen X, Ge MH, et al
    Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial.
    Clin Cancer Res. 2021 Apr 8. pii: 1078-0432.CCR-20-2950.
    PubMed     Abstract available


  55. CATENACCI DVT
    A PERFECT biomarker-focused study of neoadjuvant IO for esophagogastric cancer.
    Clin Cancer Res. 2021 Apr 6. pii: 1078-0432.CCR-21-0324.
    PubMed     Abstract available


  56. WAINBERG ZA, Fuchs CS, Tabernero J, Shitara K, et al
    Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score >/=10.
    Clin Cancer Res. 2021;27:1923-1931.
    PubMed     Abstract available


    March 2021
  57. LEI M, Siemers NO, Pandya D, Chang H, et al
    Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab{plus minus}Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer.
    Clin Cancer Res. 2021 Mar 29. pii: 1078-0432.CCR-20-2790.
    PubMed     Abstract available


  58. ZHAO M, Scott S, Evans KW, Yuca E, et al
    Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer.
    Clin Cancer Res. 2021;27:1681-1694.
    PubMed     Abstract available


  59. HUI EP, Ma BBY, Lam WKJ, Chan A, et al
    A randomized trial of adjuvant chemotherapy versus observation in patients with nasopharyngeal carcinoma with detectable post-radiotherapy pEBV DNA.
    Clin Cancer Res. 2021 Mar 10. pii: 1078-0432.CCR-20-3519.
    PubMed     Abstract available


    February 2021
  60. KLEIN S, Quaas A, Quantius J, Loser H, et al
    Deep Learning Predicts HPV Association in Oropharyngeal Squamous Cell Carcinomas and Identifies Patients with a Favorable Prognosis Using Regular H&E Stains.
    Clin Cancer Res. 2021;27:1131-1138.
    PubMed     Abstract available


  61. MUDIANTO T, Campbell KM, Webb J, Zolkind P, et al
    YAP1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas.
    Clin Cancer Res. 2021 Feb 5. pii: 1078-0432.CCR-19-4179.
    PubMed     Abstract available


  62. FERRAROTTO R, Mitani Y, McGrail DJ, Li K, et al
    Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets.
    Clin Cancer Res. 2021;27:852-864.
    PubMed     Abstract available


    January 2021
  63. WATERMANN C, Pasternack H, Idel C, Ribbat-Idel J, et al
    Recurrent HNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment Suggesting Successful Tumor Immune Evasion.
    Clin Cancer Res. 2021;27:632-644.
    PubMed     Abstract available


  64. CHAHOUD J, Gleber-Netto FO, McCormick BZ, Rao P, et al
    Whole Exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2021 Jan 13. pii: 1078-0432.CCR-20-4004.
    PubMed     Abstract available


  65. UPPALURI R, Campbell KM, Egloff AM, Zolkind P, et al
    Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.
    Clin Cancer Res. 2021;27:357.
    PubMed    


    December 2020
  66. THAKUR S, Daley B, Millo C, Cochran C, et al
    (177)Lu-DOTA-EB-TATE, A Radiolabeled Analog of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer.
    Clin Cancer Res. 2020 Dec 22. pii: 1078-0432.CCR-20-3453.
    PubMed     Abstract available


    November 2020
  67. BRADFORD D, Larkins E, Mushti SL, Rodriguez L, et al
    FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid cancers with RET Gene Mutations or Fusions.
    Clin Cancer Res. 2020 Nov 25. pii: 1078-0432.CCR-20-3558.
    PubMed     Abstract available


  68. HOLT JR, Walter V, Yin X, Marron D, et al
    Integrative analysis of microRNAs identifies clinically relevant epithelial and stromal subtypes of head and neck squamous cell carcinoma.
    Clin Cancer Res. 2020 Nov 4. pii: 1078-0432.CCR-20-0557.
    PubMed     Abstract available


    October 2020
  69. CHEN Y, Li Z, Sun Y, Zhou GQ, et al
    An immune-related gene prognostic index for head and neck squamous cell carcinoma.
    Clin Cancer Res. 2020 Oct 23. pii: 1078-0432.CCR-20-2166.
    PubMed     Abstract available


  70. TONG T, Zhong Y, Kong J, Dong L, et al
    Editor's Note: Overexpression of Aurora-A Contributes to Malignant Development of Human Esophageal Squamous Cell Carcinoma.
    Clin Cancer Res. 2020;26:5540.
    PubMed    


    September 2020
  71. DAI W, Chung DL, Chow LK, Yu VZ, et al
    Clinical Outcome-Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma.
    Clin Cancer Res. 2020 Sep 28. pii: 1078-0432.CCR-20-2854.
    PubMed     Abstract available


  72. WANG D, Muller S, Ruhul Amin ARM, Huang D, et al
    Editor's Note: The Pivotal Role of Integrin beta1 in Metastasis of Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2020;26:5052.
    PubMed    


  73. GRAY KD, McCloskey JE, Vedvyas Y, Kalloo OR, et al
    PD1 blockade enhances ICAM1-directed CAR T therapeutic efficacy in advanced thyroid cancer.
    Clin Cancer Res. 2020 Sep 4. pii: 1078-0432.CCR-20-1523.
    PubMed     Abstract available


    August 2020
  74. CHONG WQ, Lim CM, Sinha AK, Tan CS, et al
    Integration of antiangiogenic therapy with cisplatin and gemcitabine chemotherapy in patients with nasopharyngeal carcinoma.
    Clin Cancer Res. 2020 Aug 14. pii: 1078-0432.CCR-20-1727.
    PubMed     Abstract available


    July 2020
  75. HARRINGTON KJ, Kong A, Mach N, Chesney J, et al
    Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study.
    Clin Cancer Res. 2020 Jul 15. pii: 1078-0432.CCR-20-1170.
    PubMed     Abstract available


  76. UPPALURI R, Campbell KM, Egloff AM, Zolkind P, et al
    Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase 2 Trial.
    Clin Cancer Res. 2020 Jul 14. pii: 1078-0432.CCR-20-1695.
    PubMed     Abstract available


  77. WANG S, Lin Y, Xiong X, Wang L, et al
    Low-dose metformin reprograms the tumor immune microenvironment in human esophageal cancer: Results of a phase II clinical trial.
    Clin Cancer Res. 2020 Jul 9. pii: 1078-0432.CCR-20-0113.
    PubMed     Abstract available


  78. COGHILL AE, Pfeiffer RM, Proietti C, Hsu WL, et al
    Correction: Identification of a Novel, EBV-based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan.
    Clin Cancer Res. 2020;26:3496.
    PubMed    


    June 2020
  79. XU J, Bai Y, Xu N, Li E, et al
    Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
    Clin Cancer Res. 2020 Jun 19. pii: 1078-0432.CCR-19-3561.
    PubMed     Abstract available


    May 2020
  80. MCDANIEL NK, Iida M, Nickel KP, Longhurst CA, et al
    AXL mediates cetuximab and radiation resistance through tyrosine 821 and the c-ABL kinase pathway in head and neck cancer.
    Clin Cancer Res. 2020 May 21. pii: 1078-0432.CCR-19-3142.
    PubMed     Abstract available


  81. WEISS J, Sheth S, Deal AM, Grilley Olson JE, et al
    Concurrent definitive immunoradiotherapy for patients with Stage III-IV Head and Neck Cancer and Cisplatin contraindication.
    Clin Cancer Res. 2020 May 5. pii: 1078-0432.CCR-20-0230.
    PubMed     Abstract available


    April 2020
  82. GHOSH C, Kumar S, Kushchayeva Y, Gaskins K, et al
    A Combinatorial Strategy for Targeting BRAF (V600E)-Mutant Cancers with BRAF(V600E) Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib).
    Clin Cancer Res. 2020;26:2022-2036.
    PubMed     Abstract available


  83. MIGNION L, Acciardo S, Gourgue F, Joudiou N, et al
    Metabolic Imaging Using Hyperpolarized Pyruvate-Lactate Exchange Assesses Response or Resistance to the EGFR Inhibitor Cetuximab in Patient-Derived HNSCC Xenografts.
    Clin Cancer Res. 2020;26:1932-1943.
    PubMed     Abstract available


  84. SCHODER HM, Demetrio De Souza Franca P, Nakajima R, Burnazi EM, et al
    Safety and feasibility of PARP1/2 imaging with 18F-PARPi in patients with head and neck cancer.
    Clin Cancer Res. 2020 Apr 3. pii: 1078-0432.CCR-19-3484.
    PubMed     Abstract available


    March 2020
  85. YANG L, Shen C, Pettit CJ, Li T, et al
    Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy.
    Clin Cancer Res. 2020 Mar 27. pii: 1078-0432.CCR-19-3373.
    PubMed     Abstract available


  86. MITANI Y, Lin SH, Pytynia KB, Ferrarotto R, et al
    Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma.
    Clin Cancer Res. 2020;26:1175-1184.
    PubMed     Abstract available


    February 2020
  87. FRIEDMAN J, Moore EC, Zolkind P, Robbins Y, et al
    Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells.
    Clin Cancer Res. 2020;26:679-689.
    PubMed     Abstract available


    January 2020
  88. WEI T, Choi S, Buehler D, Anderson RA, et al
    A PI3K/AKT Scaffolding Protein, IQ Motif-Containing GTPase Associating Protein 1 (IQGAP1), Promotes Head and Neck Carcinogenesis.
    Clin Cancer Res. 2020;26:301-311.
    PubMed     Abstract available


    November 2019
  89. LANDA I, Pozdeyev N, Knauf JA, Haugen BR, et al
    Genetics of Human Thyroid Cancer Cell Lines-Response.
    Clin Cancer Res. 2019;25:6883-6884.
    PubMed    


  90. GARCIA C, Cormier F, Groussin L
    Genetics of Human Thyroid Cancer Cell Lines-Letter.
    Clin Cancer Res. 2019;25:6882.
    PubMed    


  91. WILLIAMS TM
    BRAF(V600E) Inhibitor Radiosensitizes Thyroid Cancer-Response.
    Clin Cancer Res. 2019;25:6557.
    PubMed    


  92. GOTTGENS EL, Rabold K, Span PN
    BRAF(V600E) Inhibitor Radiosensitizes Thyroid Cancer-Letter.
    Clin Cancer Res. 2019;25:6556.
    PubMed    


    September 2019
  93. BROSE MS, Schlumbeger M, Jeffers M, Kappeler C, et al
    Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase 3 DECISION Trial.
    Clin Cancer Res. 2019 Sep 26. pii: 1078-0432.CCR-18-3439.
    PubMed     Abstract available


    June 2019
  94. KURZROCK R, Ball DW, Zahurak ML, Nelkin BD, et al
    The VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.
    Clin Cancer Res. 2019 Jun 11. pii: 1078-0432.CCR-18-1881.
    PubMed     Abstract available


    May 2019
  95. ROBB R, Yang L, Shen C, Wolfe A, et al
    Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAF(V600E) Mutant Thyroid Cancer Cells by Constraining DNA Double-strand Break Repair.
    Clin Cancer Res. 2019 May 16. pii: 1078-0432.CCR-18-3625.
    PubMed     Abstract available


    February 2019
  96. LANDA I, Pozdeyev N, Korch C, Marlow LA, et al
    Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
    Clin Cancer Res. 2019 Feb 8. pii: 1078-0432.CCR-18-2953.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: